Testosterone Gel — Class II drug recall D-0637-2024
Ongoing recall by Teva Pharmaceuticals USA, Inc, reported 2024-08-28, distributed nationwide. Superpotent Drug
| Recall number | D-0637-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Inc, Parsippany, NJ, United States |
| Recall initiated | 2024-08-08 |
| Classified | 2024-08-16 |
| Reported by FDA | 2024-08-28 |
| Distributed | Nationwide (US) |
| Quantity | 7,080 units |
| Reason classes | potency |
| NDC | 00591-2924, 00591-2924-18, 00591-2925, 00591-2925-30, 00591-2925-32, 00591-2926, 00591-2926-25, 00591-2926-30 |
| Lot numbers | 100042386 |
| Expiration dates | 2025-06 |
Product
Testosterone Gel, 1.62%, (Alcohol 80% v/v), 30 unit-dose packets, Rx Only, Teva Pharmaceuticals, USA, Inc. North Wales, PA 19454, NDC 0591-2925-30. Packet NDC # 0591-2925-32 Carton NDC # 0591-2925-30
Reason for recall
Superpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0637-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.